Clovis Oncology (CLVS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Clovis Oncology Announces Second Quarter 2021 Operating Results
August 4, 2021 8:00 AM EDT$36.8M in Rubraca® (rucaparib) global net product revenues for Q2 2021, down 8% vs. Q2 2020, due to continuing impact of COVID-19 Phase 1/2 LuMIERE clinical study of FAP-2286 open for enrollment, first peptide-targeted radionuclide therapeutic candidate targeting FAP in clinical development Three top-line Phase 3 data read-outs for Rubraca anticipated over the next six to 18 months with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy $72.5M in net proceeds raised through at-the-market equity offering program in Q2 2021 $230.2M in cash and cash equivalents and... More
